Effective treatment of
allergic asthma and eczema
– without side effects

Airsonett® Air4 is a medical device for effective home treatment of allergic asthma and eczema. The patented TLA technology provides 99.5% clean air in the breathing zone. Your airways and immune system can rest and recuperate when you sleep, and you wake up rested, ready for a new day.

Approved in Sweden by The Swedish National Board of Health and Welfare (Socialstyrelsen) and the Swedish paediatricians’ allergy association (BLFA). Approved in the UK by The National Institute for Health and Care Excellence (NICE) and Health Improvement Scotland (NHS).

Effective

> Reducing exacerbations1
> Improved control of allergic diseases 1, 2, 3, 4
> Improved quality of life 2, 3
> No pharmacological side effects 2

Clinically proven

Airsonett Air4 is proven to reduce exacerbations and to reduce inflammation in the airways. The clinical effects are seen after 3 months (sleep improves in 1 month).

Economical

Health economics studies confirm lower treatment costs compared to pharmacological treatment options, fewer clinic visits and better control over patient symptoms.

item03_grey
Safe Non-invasive treatment without pharmacological side effects
item04_grey
Trusted Registered medical device as proof of reliability and quality
item01_grey
Easy to use A home treatment device, designed to be easy to install and use
nothing but clean air

This is how simple it is

Illustration - allergen exposure
Allergen exposure is high during sleep
Illustration - clean air
Airsonett® Air4 provides 99.5% clean air in the breathing zone
Illustration - sleeping
Your body has the opportunity to rest and recharge

Why Air4? It’s effective

Man in blue shirt

 

Dr. Robert Boyle et al

Published in Thorax (2012)

”…we have demonstrated that nocturnal control of aeroallergen exposure…can improve quality of life and reduce airway inflammation in adults and children with atopic asthma, without significant adverse effects.”

Airsonett_model_blue_back@1x
Interested in Air4?

Air4 is available either to rent or to purchase.

If you have a patient who would benefit from using Air4, please contact us here.

Contact us

News

Read the latest news on Airsonett and see where you can meet us at tradeshows or demo events.

Airsonett signs agreement with the region of Kalmar in Sweden for treatment of severe allergic asthma with TLA via public healthcare
November 20, 2019

Airsonett announced today that the company has signed an agreement with the region of Kalmar for the treatment of patients with severe allergic asthma. The agreement is the third of its kind for Airsonett in Sweden this year, for prescription of the company’s unique treatment; Temperature controlled Laminar Airflow (TLA). The technology treats severe allergic asthma patients with particle-free air.

“We are very pleased to have signed the agreement with the region of Kalmar, as the third region this year. We are also satisfied to see that the awareness of the treatment’s good results is spreading within the Swedish healthcare community and that more patients with severe allergic asthma can receive better help to achieve a better quality of life”, says Anders Due-Boje, CEO Airsonett AB.

TLA Treatment for severe asthma is part of the national guidelines for asthma treatment since 2015, and it is today prescribed to many patients in Sweden with excellent results. The treatment takes place in the home with the Airsonett Air4, a patented medical device, and fits both children and adults.

For more information:
Anders Due-Boje, CEO, Airsonett AB
Phone: +46 70 526 03 00
E-mail: anders.due-boje@airsonett.eu


 

About severe, uncontrolled asthma
Patients with severe, uncontrolled asthma treated according to Global Initiative for Asthma (GINA) step 4/5 account for approximately 3% of all patients with persistent asthma, according to recent population-based studies using administrative and prescribed databases, but account for a much larger share of asthma-related healthcare resource use and costs. Treatment alternatives for such patients include high-dose inhaled corticosteroids (ICS) and long-acting β2-antagonists (LABAs) and/or systematic corticosteroids. During the last decade, several new drugs for the treatment of severe asthma have been developed, and some of these drugs, such as anti-immunoglobulin E and anti-interleukin 5 have been included in Step 5 in the latest GINA recommendations. The costs for treatment with these biologics are however very high. Temperature-controlled laminar airflow (TLA) is a relatively new treatment for patients with severe, uncontrolled asthma. The use of TLA has shown cost-effectiveness according to National Institute for Health and Care Excellence (NICE) standards and the Swedish Dental and Pharmaceutical Benefits Agency, TLV, a central government agency whose remit is to determine whether a pharmaceutical product, medical device or dental care procedure shall be subsidized by the state.

About Airsonett
Airsonett® is a Swedish medical device company that leads the way in the development of non-pharmacologic treatment of allergic severe asthma and eczema. Airsonett® Air4 is a non-invasive device for treatment in the home, based on the patented Temperature-controlled Laminar Airflow technology (TLA). Treatment with the Airsonett® Air4 significantly reduces allergens and other airborne irritants from the patient’s breathing zone during rest and sleep. Airsonett® Air4 is a CE marked class 1 medical device intended to be used for the alleviation of symptoms of allergy-induced diseases such as allergic asthma and eczema. It adheres to relevant EU directives regarding design, function, safety and health requirements and has undergone rigorous clinical research as well as health-economic studies. Airsonett® Air4 holds a 510(k) cleared class II approval from FDA. The company’s main shareholders are SEB Venture Capital, Industrifonden and Magnus Lundberg. For more information, visit www.airsonett.eu

Patient survey: 97% have a better quality of life with Airsonett  November 15, 2019

Airsonett quality of life with asthma

Airsonett asthma treatment less medication

This year we have conducted an examination among users of Airsonett Air4 in Sweden with allergic asthma, and we are quite proud of the answers.

A majority of the users answered, of which 97% (!) state that they have a better quality of life with the treatment. A majority of the users say that have a much better quality of life. Also, 66% state that they have been able to reduce their other medication.

We should emphasize that this is an enquiry that we have performed at Airsonett and not a clinical study. If you want to read more about our clinical studies, you can find them here: https://airsonett.eu/clinical-evidence/

Airsonett signs a new agreement: patients with severe allergic asthma in Region Västra Götaland can now receive treatment with TLA via public healthcare
September 20, 2019

Region Västra Götaland is the latest in a line of Swedish regions to sign an agreement with Air-sonett for TLA treatment. The regions Stockholm and Östergötland have previously signed similar agreements. The agreement is for prescription of the company’s unique treatment, Temperature controlled Laminar Airflow (TLA), that treats severe allergic asthma patients with particle-free air. TLA Treatment for severe asthma is part of the national guidelines for asthma treatment since 2015 and it is today prescribed to more than 600 patients in Sweden with excellent results. The number of patients treated with TLA has grown fast over the last few years.

“We are pleased that Region Västra Götaland, the second biggest region in Sweden, has now signed an agreement with Airsonett. This is further evidence that the TLA treatment has wide recognition within Swedish asthma care. We look forward to helping more patients with severe allergic asthma in additional regions”, says Anders Due-Boje, CEO Airsonett AB.

 

For more information:
Anders Due-Boje, CEO, Airsonett AB
Phone: +46 70 526 03 00
E-mail: anders.due-boje@airsonett.eu

 

About severe, uncontrolled asthma
Patients with severe, uncontrolled asthma treated according to Global Initiative for Asthma (GINA) step 4/5 account for approximately 3% of all patients with persistent asthma, according to recent population-based studies using administrative and prescribed databases, but account for a much larger share of asthma-related healthcare resource use and costs. Treatment alternatives for such patients include high-dose inhaled corticosteroids (ICS) and long-acting β2-antagonists (LABAs) and/or systematic corticosteroids. During the last decade, several new drugs for the treatment of severe asthma have been developed, and some of these drugs, such as anti-immunoglobulin E and anti-interleukin 5 have been included in Step 5 in the latest GINA recommendations. The costs for treatment with these biologics are however very high. Temperature-controlled laminar airflow (TLA) is a relatively new treatment for patients with severe, uncontrolled asthma. The use of TLA has shown cost-effectiveness according to National Institute for Health and Care Excellence (NICE) standards and the Swedish Dental and Pharmaceutical Benefits Agency, TLV, a central government agency whose remit is to determine whether a pharmaceutical product, medical device or dental care procedure shall be subsidized by the state.

News